DEFA14A: Royalty Pharma to Acquire External Manager, Projects Strong 2024 Portfolio Receipts

Royalty Pharma announces the acquisition of its external manager, RP Management, and provides a corporate update, projecting strong portfolio receipts for 2024 and outlining future capital deployment plans.

Summary

• Royalty Pharma plc issued a corporate update in conjunction with its participation at the 43rd Annual J.P. Morgan Healthcare Conference.
• The company is acquiring its external manager, RP Management, for approximately $1.1 billion, expected to close in the second quarter of 2025.
• This internalization is projected to result in cumulative cash savings of over $1.6 billion over ten years.
• 2024 Portfolio Receipts are expected to be approximately $2.8 billion, at the high end of the previous guidance range.
• Royalty Receipts growth for 2024 is expected to be around 13%.
• The company announced approximately $2.8 billion in royalty transactions across eight deals in 2024.
• A new $3 billion share repurchase program has been authorized, with an intention to repurchase $2 billion in 2025, subject to market conditions.
• The company added royalties on eight new therapies in 2024, including four development-stage royalties with a peak royalty potential of over $1.2 billion.
• The company is maintaining its investment grade credit rating and is committed to growing its dividend by mid-single digits annually.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Royalty Pharma, driven by the acquisition of its external manager, strong portfolio performance, and a commitment to returning capital to shareholders. The company's strategic initiatives and financial discipline contribute to a favorable sentiment.

Positives

• The acquisition of RP Management is expected to result in significant cash savings, exceeding $1.6 billion over ten years.
• Internalization strengthens shareholder alignment, improves governance, and simplifies the company's structure.
• The company expects strong portfolio receipts for 2024, reaching approximately $2.8 billion.
• The company has a strong track record of capital deployment, with approximately $2.8 billion in royalty transactions in 2024.
• The new share repurchase program demonstrates confidence in the company's outlook and commitment to returning capital to shareholders.
• The company has a diverse and growing development-stage pipeline with significant potential.
• The company is committed to growing its dividend by mid-single digits annually.

Negatives

• The acquisition of RP Management requires a significant upfront investment of approximately $1.1 billion.
• The share repurchase program is subject to market conditions, which could impact the actual value of shares repurchased.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
• The company's reliance on third-party data and estimates carries inherent risks regarding accuracy and reliability.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other variable circumstances that could cause actual results to differ materially.
• The transaction to acquire RP Management is subject to shareholder approval.
• The company's performance is dependent on the success of its royalty investments, which are subject to clinical and regulatory risks.
• Market conditions could impact the company's ability to execute its share repurchase program.
• The company faces competition in the biopharmaceutical royalty space.

Future Outlook

Royalty Pharma aims to continue delivering attractive returns above its cost of capital, balancing royalty acquisitions with increased return of capital to shareholders through share repurchases and dividends. The company is targeting 10% or more top-line CAGR through capital deployment.

Management Comments

• Internalizing the Manager is the next step in our evolution.

Industry Context

Royalty Pharma operates in the biopharmaceutical industry, where royalty financing is becoming an increasingly important source of capital for companies. The company's model provides an alternative to traditional debt and equity financing, offering non-dilutive capital and shared risk in drug development and commercialization.

Comparison to Industry Standards

• The acquisition of RP Management implies a significant discount to alternative asset managers on a comparison to both trading and transaction multiples.
• The implied transaction multiples for RP Management are ~23x Price/FRE and ~8-10x 2026E EBITDA, which is lower than the median multiples for alternative asset managers.
• Comparable alternative asset managers include Ares, Blackstone, Blue Owl, Brookfield Asset Management, and EQT.
• Alternative asset manager acquisitions include Bridgepoint Group plcs acquisition of Energy Capital Partners, TPG Inc.s acquisition of Angelo Gordon, EQT ABs acquisition of LSP, EQT ABs acquisition of Exeter Property Group and Brookfield Asset Management Incs acquisition of Oaktree Capital Group, LLC.

Stakeholder Impact

• Shareholders are expected to benefit from increased cash savings, enhanced returns, and improved governance resulting from the internalization of the manager.
• Employees of RP Management will become part of the integrated company, ensuring long-term continuity of personnel and operations.
• The company's continued investment in royalty transactions supports innovation in the biopharmaceutical industry.
• The company's commitment to growing its dividend provides a consistent return to shareholders.

Next Steps

• Shareholder approval of the transaction to acquire RP Management.
• Closing of the RP Management acquisition, expected in the second quarter of 2025.
• Execution of the $3 billion share repurchase program, with an intention to repurchase $2 billion in 2025.
• Advancement of key pipeline assets through clinical trials and regulatory approvals.
• Monitoring and potential investment in new royalty opportunities.

Key Dates

Keywords

Royalty Pharma, RP Management, acquisition, internalization, portfolio receipts, royalty transactions, share repurchase, capital deployment, royalties, biopharma